Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
That can affect strength, metabolic health, and how you feel day to day
How is AOD-9604 different from full-length growth hormone
Summary: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) that, based on Phase 2 trial data, produces significant appetite suppression and progressive weight loss, alongside gastrointestinal side effects that are most prominent during dose escalation
After five weeks, the results were incredible
However, Glp1r/ mice treated with the GLP-1/Gcg coagonist experienced a reduction in body weight and fat mass but did not have improvements in glucose tolerance indicating that GLP-1R agonism is required to counteract the hyperglycemic effects of GcgR agonism (Day et al., 2013)
